Login / Signup

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.

Devendra K HiwaseChristopher N HahnElizabeth Ngoc Hoa TranRakchha ChhetriAnmol BaranwalAref A Al-KaliKirsty M SharplinDariusz LadonRachel HollinsPatricia T GreippMonika M KutynaHassan B AlkhateebTalha BadarPaul Po-Shen WangDavid Morrall RossDeepak SinghalNaranie ShanmuganathanPeter G BardyAshanka BeligaswatteDavid T YeungMark R LitzowAbhishek A MangaonkarPratyush GiriCindy H LeeAngelina YongNoemi HorvathNimit SinghalRaghu GowdaWilliam J HoganNaseema GangatMirinal S PatnaikKebede H BegnaIng Soo TiongAndrew H WeiSharad KumarAnna L BrownHamish S ScottDaniel ThomasChung Hoow KokAyalew TefferiMithun Vinod Shah
Published in: Blood (2022)
Keyphrases
  • bone marrow
  • dendritic cells
  • low grade
  • acute myeloid leukemia
  • single molecule
  • stem cells
  • immune response
  • cell therapy
  • high grade
  • drug induced
  • replacement therapy